Objective: To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC). Methods: L-CLA testing was conducted in two MS patient cohorts. In the MSFC Validation Study, 137 participants from a Phase III trial of inteferon beta-1a (Avonex) for relapsing-remitting MS were followed. A second cohort included 65 patients with secondary progressive MS who participated in a substudy of the International MS Secondary Progressive Avonex Controlled Trial (IM-PACT). The total number of letters read correctly at four contrast levels (100, 5, 1.25, and 0.6%) was correlated with Expanded Disability Status Scale (EDSS), MSFC, Sickness Impact Profile, Multiple Sclerosis Quality of Life Inventory, and brain parenchymal fraction (BPF), as determined by MRI. Results: Low-and high-contrast letter acuity scores correlated with BPF at follow-up in the MSFC Validation Study (5%: r ϭ 0.40, p Ͻ 0.0001; 100%: r ϭ 0.31, p ϭ 0.0002). L-CLA also correlated with EDSS (5%: r ϭ Ϫ0.35, p Ͻ 0.0001; 1.25%: r ϭ Ϫ0.26, p ϭ 0.0003) and MSFC (5%: r ϭ 0.47, p Ͻ 0.0001; 1.25%: r ϭ 0.45, p Ͻ 0.0001). In the IMPACT Substudy, change in L-CLA scores from baseline to year 1 predicted subsequent change in the EDSS from year 1 to 2 at the 5% (p ϭ 0.0142) and the 1.25% (p ϭ 0.0038) contrast levels, after adjusting for change in MSFC scores from baseline to year 1. Conclusions: Low-contrast letter acuity (L-CLA) scores demonstrate concurrent and predictive validity in patients with relapsing-remitting and secondary progressive multiple sclerosis (MS). L-CLA testing provides additional information relevant to the MS disease process that is not entirely captured by the Multiple Sclerosis Functional Composite.
The most widely used outcome measure in multiple sclerosis (MS), the Expanded Disability Status Scale (EDSS), has been criticized for its heavy reliance on ambulation, problems with reliability, and unequal steps in the scale, making the meaning of a change complicated. A Multiple Sclerosis Clinical Outcomes Assessment Task Force was appointed to make recommendations for improved clinical outcome measures for use in future MS clinical trials. The task force identified the four major clinical dimensions of MS, which include arm, leg, cognitive, and visual function. 1 A meta-analysis was initiated. Even though many datasets contained measures of visual acuity, the visual acuity data did not show sufficient change over time, nor did it correlate with changes in the EDSS. The Multiple Sclerosis Functional Composite (MSFC), ultimately recommended by the task force, consists of the remaining three dimensions, the 25-Foot Timed Walk, the 9-Hole Peg Test, and the Paced Auditory Serial Addition Test (PA-SAT3), to measure cognitive function. 2 Several studies have shown that measures relating to low-contrast vision may be the most sensitive measures of visual dysfunction in patients with MS. [3] [4] [5] [6] [7] [8] Measures used to elicit deficits in low-contrast vision are contrast sensitivity and contrast letter acuity (CLA; the identification of gray letters on a white background). The Low Contrast Sloan Letter Charts are sensitive and reliable in assessing CLA in patients with MS. 9,10 Furthermore, CLA testing was examined as potential candidate for the MSFC crosssectionally in the Multiple Sclerosis Vision Prospective Cohort (MVP cohort). 10 Also, worse scores in CLA were significantly associated with secondary progressive MS phenotype in the MVP cohort. 11 Although cross-sectional analyses have provided data in support of CLA testing as a candidate visual component for the MSFC, examination of predictive and concurrent validity is also critical to the assessment of candidate outcome measures.
Methods. MSFC Validation Study.
Eligible subjects were patients who participated in the Phase III clinical trial of interferon beta-1a (IFN␤-1a; Avonex, Biogen, Cambridge, MA) and who completed the 2-year (week-104) examination. This requirement assured us that each patient had baseline, year 1, and year 2 visits and, although a subgroup of the original cohort, were consecutive patients entered into the trial. The original cohort consisted of 301 subjects. Patients were enrolled at different times; hence, not all patients had completed their 2-year exam when the study was terminated early. At that time, 172 subjects at four clinical sites completed the 2-year exam. The visits on this population used in this report were conducted approximately 8 years post baseline.
IMPACT Substudy. A second set of data were collected via a substudy of the IMPACT Trial. The primary objective of IMPACT was to determine whether weekly IM treatment with Avonex (IFN␤-1a), when compared with placebo, was effective in slowing the progression of secondary progressive MS, as determined by the MSFC. The primary aim of the vision substudy was to examine the validity and feasibility of CLA testing as a measure of visual function in patients with secondary progressive MS. Subjects were between ages 18 and 60 and had been diagnosed with secondary progressive MS and an EDSS scores at entry between 3.5 and 6.5. Approximately 440 subjects were recruited for the IMPACT Trial. CLA data were collected on 65 patients in six participating clinics; 52 patients completed 2-year visits for the vision substudy.
Study protocol. Both studies were approved by institutional review boards at each clinical site, with the participants signing the informed consent. In the MSFC Validation Study, patients reported for a single follow-up visit to the clinic. At the clinic visit, the examining neurologist recorded the EDSS and functional system scores, classified the case as relapsing-remitting or secondary progressive, and recorded type and dates of disease-modifying drug therapy. A trained technician administered the components of the MSFC as well as the CLA testing. Patients completed the Sickness Impact Profile (SIP) quality-of-life measure. A cranial MRI scan was performed, using acquisition parameters as similar as possible to the original clinical trial. The brain parenchymal fraction (BPF), defined as the ratio of brain parenchymal volume to the total volume within the brain surface contour, was used as a marker of brain atrophy. Patients who were unable or unwilling to visit the clinic completed the self-administered version of the EDSS as well as the SIP. For the patients who had died, the examining physician interviewed family members and assigned an EDSS score based on the patient's condition prior to death.
In the IMPACT Substudy, subjects were evaluated every 3 months. Baseline assessments for the substudy were performed at months 0 to 9 (initial CLA measurements were not performed at month 0 in all patients due to institutional review board approval delays). The EDSS and the MSFC were administered every 3 months. The Multiple Sclerosis Quality of Life Inventory (MSQLI), designed to be self-administered, was obtained at months 0, 12, and 24.
CLA testing. The Low Contrast Sloan Letter Charts (Precision Vision, LaSalle, IL) were used to assess visual function. Each Sloan Chart has gray letters of progressively smaller size on a white background, and each chart represents a different contrast level. The charts are based on the format of the Bailey-Lovie and Early Treatment for Diabetic Retinopathy Study (ETDRS) visual acuity charts, the standard used in ophthalmology clinical trials. Each chart is printed on a 14 1 ⁄4 ϫ 13 1/2-inch durable laminated board or is available for use with a retro-illuminated cabinet. Four charts, including 100% (measures high-contrast visual acuity), 5%, 1.25%, and 0.6% contrast levels, were chosen for this study. A standardized testing protocol, based on testing for the ETDRS visual acuity charts, was used. Patients were seated 2 meters from the chart, with the white portion of the chart illuminated to 80 to 100 foot-candles. Patients were asked to wear their usual distance glasses or contact lenses for the testing session. For each of the four charts, the number of letters identified correctly was recorded. The maximum score obtainable for each of the charts is 60 letters.
Data analysis. Statistical analyses were performed using SAS 8.1 for PC (Cary, NC). Spearman rank correlation coefficients were computed to assess relationships between the outcome measures and CLA in cross-sectional analyses. Repeated measures analyses were performed to assess construct validity longitudinally. To assess predictive validity, change from year 1 to year 2 in the EDSS, after adjusting for change in the MSFC from baseline to year 1, was regressed on the change in the CLA scores from baseline to year l.
Results. Case ascertainment. Of the 172 eligible patients in the MSFC Validation Study, 137 were seen in the clinics with measurements for the EDSS, MSFC, SIP, CLA, and MRI. Sixteen patients completed selfassessments for the EDSS and the SIP. Seven patients had died, and 12 patients either could not be located or refused to participate. In the IMPACT Substudy, 65 patients had CLA testing.
Patient demographics and characteristics. In the MSFC Validation Study, the mean age at entry into the Phase III trial was 36.1 Ϯ 6.8 years, with 77.3% of the patients being women. The average disease duration was 6.3 Ϯ 5.6 years. There were no significant differences in age, gender, or disease duration among the four groups (seen in clinic, self-assessment, died, and lost to follow-up), with the exception of disease duration, which was different between the patients seen in the clinic (5.8 Ϯ 5 years) and the patients completing self-assessments (9.9 Ϯ 8.4 years). Table 1 shows the baseline characteristics of the 137 patients seen in the clinic at the 8-year follow-up and their follow-up characteristics as well as the patient characteristics of the 65 patients in the IMPACT Substudy who had CLA testing, including measures of binocular visual function. As in recent ophthalmologic epidemiologic studies, binocular testing was used in this investigation to minimize patient fatigue, to best assess visual function as is present for daily activities, and to potentially capture both afferent and efferent dysfunction. 12, 13 In the IMPACT Substudy, binocular L-CLA scores at 1.25% contrast correlated with EDSS scores at the 12-month visit (r ϭ Ϫ0.43, p ϭ 0.001), but monocular scores for better eyes (r ϭ Ϫ0.17, p ϭ 0.26) and worse eyes (r ϭ Ϫ0.29, p ϭ 0.05) did not correlate significantly with overall neurologic function. 10 As expected, CLA scores declined with decreasing contrast level, as shown in table 1. The 0.6% chart was not considered in the primary analyses as a total of 49.5% of the patients in the MSFC Validation Study and the IMPACT Substudy were unable to read any letters on this chart.
Associations between study variables and CLA. The variables of interest were EDSS, MSFC, MRI parameters, SIP, and MSQLI. Table 2 provides the Spearman correlation coefficients between the various clinical measures and CLA scores for the MSFC Validation Study and IMPACT Substudy. Except for the PASAT3 in the IMPACT Substudy, all correlations were significant at the 5 and the 1.25% contrast levels. The correlations were consistently higher for CLA vs MSFC than for CLA vs EDSS.
Other outcomes. Outcome measures, including SIP, MSQLI, and MRI, were evaluated for their degrees of association with CLA scores separately for each study. In the MSFC Validation Study, associations between L-CLA at 5 and 1.25% contrast and the SIP were observed (p Ͻ 0.0001). In addition, at the 8-year follow-up visit, higher correlations between BPF and L-CLA were observed for the 5% contrast (r ϭ 0.40, p Ͻ 0.0001) and 1.25% contrast (r ϭ 0.31, p ϭ 0.0002) than for high-contrast letter acuity (100% contrast). In the IMPACT Substudy, correlations were observed between CLA scores and the Impact of Visual Impairment Subscale of the MSQLI (p Ͻ 0.05).
To further determine construct validity, the relation of CLA scores to disease severity (EDSS Յ 6 vs EDSS Ͼ 6) was examined. Whereas high-contrast letter acuity (100% level) showed no difference, mean scores for the 5 and 1.25% contrast levels were higher for patients with EDSS scores of Յ6 compared with those Ͼ6 (5% level: 41 Ϯ 10 vs 34 Ϯ 12, p Ͻ 0.0001; 1.25% level: 24 Ϯ 12 vs 17 Ϯ 12, p ϭ 0.0013).
Similarly, BPF at the end of the Phase III clinical trial of IFN␤-1a correlated with CLA scores obtained at the time of follow-up (100%: r ϭ 0.27, p ϭ 0.0031; 5%: r ϭ 0.26, p ϭ 0.0045; 1.25%: r ϭ 0.17, p ϭ 0.0574).
Predictive validity. To assess predictive validity in the IMPACT Substudy, change in CLA from baseline to year 1 was used to predict subsequent change in EDSS from year 1 to year 2, after adjusting for change in the MSFC from baseline to year 1. After adjusting for the MSFC, both 5 and 1.25% contrast levels add significant information to the MSFC in predicting subsequent change in the EDSS (table 3) .
Discussion. The Low Contrast Sloan Letter
Charts are a highly reliable method of testing visual function in patients with MS and have demonstrated construct validity in cross-sectional studies. 9, 10 The current investigation provides further evidence for concurrent and predictive validity for CLA testing.
In our Phase III trial substudies, L-CLA scores were significantly yet modestly correlated with neurologic impairment and were consistently lower for patients with MS who were no longer ambulatory. These observations also support construct validity for CLA testing in MS and suggest that declines in visual function parallel, at least to some extent, changes in other dimensions of neurologic function. Similar correlations between CLA scores and MSFC/EDSS were observed in the MVP cohort. 10 The significant association of CLA scores and BPF provides evidence that visual dysfunction, like other dimensions of neurologic impairment, is associated with brain atrophy and axonal/neuronal loss. The relation of visual function to global brain MRI parameters that assess lesion burden and axonal loss is currently under investigation in the MVP Cohort Study. Studies are under way to examine the relation of visual function to biologic markers of retinal and optic nerve axonal loss. Importantly, our results also indicate that losses of binocular low-contrast vision have a negative impact on health-related quality of life, as measured by the SIP. Although scores from the Short Form-36 (SF-36; core scale of the MSQLI) were not significantly associated with CLA in the IMPACT Substudy, larger studies have demonstrated significant correlations with SF-36 Physical Components Summary scores. 14 From our previous experience in developing the MSFC, it has become clear that a sensitive measure to evaluate visual function is needed for clinical trials outcome assessment. Several studies have shown that measures relating to low-contrast vision are sensitive to change. Contrast sensitivity and letter acuity tests demonstrate abnormalities in high pro-portions of patients with Snellen acuities of 20/20 or better and are frequently abnormal even in eyes with normal visual evoked potentials. Tests of lowcontrast vision also generate results that are predictive of reading rate and other aspects of "real life" visual function. Routine tasks such as driving at dusk, viewing the TV, or simply differentiating objects at varying illuminations (i.e., seeing a car in hazy visibility) may be affected by losses of lowcontrast vision. In the setting of low-contrast acuity loss, patients may have visual impairment in dim light that is not apparent on testing of high-contrast acuity or visual fields.
Collectively, results from both cross-sectional and longitudinal studies demonstrate that CLA testing using the Low Contrast Sloan Letter Charts is a valid and sensitive method for assessing visual function in patients with MS. CLA represents a strong candidate visual component for the MSFC. Largescale longitudinal studies are currently under way, evaluating CLA and its contribution to the MSFC over time in clinical trials. 
